Legal & General Group
LUCD icon

Legal & General Group’s Lucid Diagnostics LUCD Stock Holding History

Legal & General Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Buy
14,580
+8,265
+131% +$8.91K ﹤0.01% 3212
2026
Q1 		$7.26K Sell
6,315
-840
-12% -$1.07K ﹤0.01% 3243
2025
Q4 		$7.8K Hold
7,155
– – ﹤0.01% 3296
2025
Q3 		$7.23K Hold
7,155
– – ﹤0.01% 3337
2025
Q2 		$8.23K Buy
+7,155
New +$9.24K ﹤0.01% 3334
2022
Q2 		– Sell
-500
Closed -$2K – 3599
2022
Q1 		$2K Hold
500
– – ﹤0.01% 3550
2021
Q4 		$3K Buy
+500
New +$4.06K ﹤0.01% 3562

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Legal & General Group's LUCD Position: Q2 2026 in Review

Legal & General Group increased its Lucid Diagnostics (LUCD) stake by 131% in Q2 2026, buying an estimated $8.91K and bringing the position to 14,580 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3212.

Legal & General Group first reported a position in LUCD in Q4 2021 and has held it in 7 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Legal & General Group held 14,580 shares of Lucid Diagnostics worth $15.6K as of Q2 2026.
  • Legal & General Group bought 8,265 Lucid Diagnostics shares in Q2 2026, an estimated $8.91K.
  • Lucid Diagnostics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3212 holding.
  • Legal & General Group first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 7 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.